|
|
Vol. 13.20 – 3 June, 2022
|
|
|
|
|
|
|
|
Researchers specifically deleted androgen receptor in smooth muscle cells of the adult mouse prostate under two tumorigenic conditions, namely, the Hi-Myc genetic model and the T + E2 hormonal carcinogenesis model. [Cell Reports]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
The authors investigated whether DHX9 modulated prostate cancer cell transcriptome and performed RNA-sequencing analyses upon DHX9 silencing in the androgen-responsive cell line LNCaP.
[Journal of Experimental & Clinical Cancer Research]
|
|
|
|
|
|
Using high-throughput circRNA sequencing, scientists previously identified 18 urine extracellular vesicle circRNAs that were increased in patients with prostate cancer compared with those with benign prostatic hyperplasia.
[Cell Death & Disease]
|
|
|
|
|
|
Investigators assessed radiosensitisation of androgen receptor (AR)-positive, estrogen receptor (ER)-positive cell lines using pharmacologic or genetic inhibition/degradation of AR and/or ER. [British Journal of Cancer]
|
|
|
|
|
|
Both the compounds A-chitosan (Ch and B-Ch showed activity toward estrogen negative breast cancer and androgen negative prostate cancer cell lines.
[Colloids and Surfaces B-Biointerfaces]
|
|
|
|
|
|
LNCaP-LA showed X-ray resistance compared to LNCaP and sensitivity to carbon ion beams.
[Journal of Radiation Research]
|
|
|
|
|
|
A luciferase reporter assay revealed that MNX1 Antisense RNA 1 (MNX1‑AS1) could target miR‑2113 and negatively interacted with miR‑2113 in prostate cancer cells.
[Molecular Medicine Reports]
|
|
|
|
|
|
Scientists identified Gremlin1 as a ligand for fibroblast growth factor receptor 1, which promoted lineage plasticity and drove castration resistance. [Nature Cancer]
|
|
|
|
|
|
|
|
|
Prostate cancer cells often exhibit alterations in DNA damage response genes including ataxia telangiectasia mutated, correlating with aggressive disease phenotype. [International Journal of Biochemistry & Cell Biology]
|
|
|
|
|
|
|
|
ANGLE plc announced it has signed a master clinical study agreement with Solaris Health Holdings, LLC and joinder agreements with MidLantic Urology LLC, to collaborate and conduct clinical studies in prostate cancer and as a potential route to market in the United States.
[ANGLE plc (BioSpace)]
|
|
|
|
|
|
Janux Therapeutics, Inc. announced that the FDA has cleared the company’s investigational new drug application for its lead product candidate, JANX007, a PSMA-TRACTr in development for the treatment of metastatic castration-resistant prostate cancer. [Janux Therapeutics, Inc.]
|
|
|
|
|
|
|
|
September 11 – September 16, 2022 Ventura, California, United States
|
|
|
|
|
|
|
|
|
|
|
La Jolla Institute for Immunology – La Jolla, California, United States
|
|
|
|
|
|
|
German Cancer Research Center in the Helmholtz Association – Heidelberg, Germany
|
|
|
|
|
|
|
CRUK Manchester Institute – Manchester, United Kingdom
|
|
|
|
|
|
|
Memorial Sloan Kettering Cancer Center – New York, New York, United States
|
|
|
|
|
|
|
Marlene and Stewart Greenebaum Comprehensive Cancer Center – Baltimore, Maryland, United States
|
|
|
|
|
|